Announcement on Outline of the Q3 2025 Performance Briefing
Filed with SSE · · 3 pages · Chinese
Summary by 6ix AI
The company held an interactive performance briefing on December third, where executives addressed investor questions about recent sales and market conditions. The announcement includes responses to investor inquiries about revenue declines and future growth strategies. The company aims to enhance its profitability through various initiatives, including increased research and development efforts.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Tibet Rhodiola Pharmaceutical Holding Co. on 6ix
Earlier from Tibet Rhodiola Pharmaceutical
- Announcement on Convening the Q3 2025 Performance Briefing
- Announcement on Resolutions of the 11th Meeting of the 8th Board of Directors
- Announcement on Outline of the 2025 Semi-annual Performance Briefing
- Announcement on Convening the 2025 Semi-annual Performance Briefing
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
Later from Tibet Rhodiola Pharmaceutical
- Announcement on the Continued Inclusion of the Company’s Product Xinhuaosu in the National Medical Insurance Drug Catalog
- Plan for Repurchasing Shares through Call Auction
- Announcement on Shareholding of Top 10 Shareholders and Top 10 Holders of Shares Without Sales Limit Concerning Shares Repurchase
- Announcement on Initially Repurchasing Shares
- Announcement on Progress in Providing Guarantee for Holding Subsidiary
Follow Tibet Rhodiola Pharmaceutical into a list and get an email when it puts out news.
Follow Tibet Rhodiola Pharmaceutical